Compare · APLS vs NVO
APLS vs NVO
Side-by-side comparison of Apellis Pharmaceuticals Inc. (APLS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 36.5x APLS ($5.25B).
- Over the past year, APLS is up 111.8% and NVO is down 43.1% - APLS leads by 154.9 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 2 for APLS).
- Both have 25 recent analyst ratings on file.
- Company
- Apellis Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $41.05-0.05%
- $42.94-1.84%
- Market cap
- $5.25B
- $191.82B
- 1M return
- +0.48%
- -6.14%
- 1Y return
- +111.85%
- -43.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 2
- 7
- Recent ratings
- 25
- 25
Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest APLS
- Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.
- SEC Form 15-12G filed by Apellis Pharmaceuticals Inc.
- Director Dunlop A. Sinclair returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- VP/Chief Accounting Officer Chopas James George was granted 38,244 shares and returned 76,650 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Dolsten Mikael returned 14,312 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Research and Development Meltzer Leslie returned 174,854 shares to the company and was granted 67,830 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Fonteyne Paul R. returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Sullivan Timothy Eugene was granted 159,080 shares and returned 270,413 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Machiels Alec returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Scientific Officer Deschatelets Pascal was granted 90,040 shares and returned 135,445 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates